Objective:This study aimed to evaluate the diagnostic accuracy of MRI in the detection of nodal metastasis in urothelial bladder cancer(UBC)and to assess the long-term oncological outcomes of upfront radical cystectom...Objective:This study aimed to evaluate the diagnostic accuracy of MRI in the detection of nodal metastasis in urothelial bladder cancer(UBC)and to assess the long-term oncological outcomes of upfront radical cystectomy(RC)in patients with clinical lymph node-positive(cN^(+))muscle-invasive UBC.Methods:A retrospective analysis of 1053 consecutive UBC patients treated with RC between January 1,2004 and January 31,2014 was performed.Radiological,clinical,pathological data and survival outcomes of cN^(+) patients were collected.Cox regression analyses were used to assess the impact of the radiological,clinical,and pathological variables on survival.Results:A total of 233(22%)patients were diagnosed with cN^(+) UBC with a mean age of 57.3(standard deviation 8.1)years,of whom 144(62%)were found to have pathologically positive lymph nodes at final pathology.Adjuvant chemotherapy was administered to 58(25%)patients.The sensitivity,specificity,positive predictive value,and negative predictive value of MRI to detect pathological lymph node-positive disease were 51%,88%,62%,and 83%,respectively.The overall accuracy was 79% with a calculated area under the curve of 70%.The median follow-up period was 17.0(interquartile range 8.2e58.7)months.During this period,54(23%)patients developed local recurrence while 56(24%)experienced distant metastasis and the estimated 1-,3-,5-,and 10-year recurrence-free survival for cN^(+) patients were 78%,56%,51%,and 48%,respectively.On multivariate analysis,advanced pT stage(pT3e4 vs.pT2)was the only independent predictor of recurrence-free survival.Conclusion:Despite its potential in preoperative assessment of muscle-invasive UBC,MRI showed limited sensitivity for detecting node-positive disease.Notably,in patients with MRIdetected cN^(+) UBC,those who underwent upfront RC demonstrated long-term survival outcomes comparable to those treated with neoadjuvant chemotherapy followed by consolidative cystectomy in previously published studies.展开更多
Objective This study aimed to compare the effectiveness of adjuvant chemoradiotherapy(CRT)and adjuvant chemotherapy(ChT)for T3–4/N+gastric cancer(GC)following D2/R0 dissection,and identify the specific subgroups that...Objective This study aimed to compare the effectiveness of adjuvant chemoradiotherapy(CRT)and adjuvant chemotherapy(ChT)for T3–4/N+gastric cancer(GC)following D2/R0 dissection,and identify the specific subgroups that could benefit from adjuvant CRT.Methods All eligible patients were divided into the CRT group and ChT group.We assessed the survival outcomes and patterns of recurrence for each group,and determined the prognostic factors for survival by performing Cox proportional risk regression analyses.Results A total of 192 gastric cancer patients were included in the study.The estimated 3-year and 5-year disease-free survival(DFS)probabilities in the CRT and ChT groups were 52.9%vs.36.7%(P=0.024)and 41.2%vs.31.1%(P=0.148),respectively,and the estimated 3-year and 5-year overall survival(OS)probabilities were 82.4%vs.70.0%(P=0.044)and 52.0%vs.35.6%(P=0.022).Patients in the CRT group had a lower risk of locoregional recurrence than those in the ChT group(20.6%vs.34.4%;P=0.031).The subset analyses revealed that patients with stage N1–2 disease were more likely to benefit from adjuvant CRT than from adjuvant ChT(DFS:53.1%vs.36.4%;P=0.039;OS:53.1%vs.38.6%;P=0.036).Conclusion For locally advanced gastric cancer patients with LN+,adjuvant CRT showed superior survival benefits compared with adjuvant ChT alone.Patients with N1–2 achieved better survival from adjuvant CRT.展开更多
文摘Objective:This study aimed to evaluate the diagnostic accuracy of MRI in the detection of nodal metastasis in urothelial bladder cancer(UBC)and to assess the long-term oncological outcomes of upfront radical cystectomy(RC)in patients with clinical lymph node-positive(cN^(+))muscle-invasive UBC.Methods:A retrospective analysis of 1053 consecutive UBC patients treated with RC between January 1,2004 and January 31,2014 was performed.Radiological,clinical,pathological data and survival outcomes of cN^(+) patients were collected.Cox regression analyses were used to assess the impact of the radiological,clinical,and pathological variables on survival.Results:A total of 233(22%)patients were diagnosed with cN^(+) UBC with a mean age of 57.3(standard deviation 8.1)years,of whom 144(62%)were found to have pathologically positive lymph nodes at final pathology.Adjuvant chemotherapy was administered to 58(25%)patients.The sensitivity,specificity,positive predictive value,and negative predictive value of MRI to detect pathological lymph node-positive disease were 51%,88%,62%,and 83%,respectively.The overall accuracy was 79% with a calculated area under the curve of 70%.The median follow-up period was 17.0(interquartile range 8.2e58.7)months.During this period,54(23%)patients developed local recurrence while 56(24%)experienced distant metastasis and the estimated 1-,3-,5-,and 10-year recurrence-free survival for cN^(+) patients were 78%,56%,51%,and 48%,respectively.On multivariate analysis,advanced pT stage(pT3e4 vs.pT2)was the only independent predictor of recurrence-free survival.Conclusion:Despite its potential in preoperative assessment of muscle-invasive UBC,MRI showed limited sensitivity for detecting node-positive disease.Notably,in patients with MRIdetected cN^(+) UBC,those who underwent upfront RC demonstrated long-term survival outcomes comparable to those treated with neoadjuvant chemotherapy followed by consolidative cystectomy in previously published studies.
文摘Objective This study aimed to compare the effectiveness of adjuvant chemoradiotherapy(CRT)and adjuvant chemotherapy(ChT)for T3–4/N+gastric cancer(GC)following D2/R0 dissection,and identify the specific subgroups that could benefit from adjuvant CRT.Methods All eligible patients were divided into the CRT group and ChT group.We assessed the survival outcomes and patterns of recurrence for each group,and determined the prognostic factors for survival by performing Cox proportional risk regression analyses.Results A total of 192 gastric cancer patients were included in the study.The estimated 3-year and 5-year disease-free survival(DFS)probabilities in the CRT and ChT groups were 52.9%vs.36.7%(P=0.024)and 41.2%vs.31.1%(P=0.148),respectively,and the estimated 3-year and 5-year overall survival(OS)probabilities were 82.4%vs.70.0%(P=0.044)and 52.0%vs.35.6%(P=0.022).Patients in the CRT group had a lower risk of locoregional recurrence than those in the ChT group(20.6%vs.34.4%;P=0.031).The subset analyses revealed that patients with stage N1–2 disease were more likely to benefit from adjuvant CRT than from adjuvant ChT(DFS:53.1%vs.36.4%;P=0.039;OS:53.1%vs.38.6%;P=0.036).Conclusion For locally advanced gastric cancer patients with LN+,adjuvant CRT showed superior survival benefits compared with adjuvant ChT alone.Patients with N1–2 achieved better survival from adjuvant CRT.
